Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2016 by Genentech, Inc.
AbbVie (prior sponsor, Abbott)
Information provided by (Responsible Party):
Genentech, Inc. Identifier:
First received: August 10, 2012
Last updated: October 4, 2016
Last verified: October 2016
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: May 2020
  Estimated Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)